Immunomedics Inc. (IM3:FWB2)

HEALTH CARE: PHARMACEUTICALS
SIC: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

300 AMERICAN RD MORRIS PLAINS, NJ 07950

Immunomedics Inc. develops, manufactures and markets monoclonal antibody-based products for detection and treatment of cancer and other diseases. Focuses on therapeutic antibodies designed to carry radioisotopes, chemotherapeutic agents, toxins and other substances to a specific disease site or organ system.

Data as of 2019-12-02 12:49:09 -0500
Market Cap3.631 Billion Shares Outstanding193.354 Million Avg 30-day Volume
P/E Ratio Dividend Yield EPS-1.864
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA 52-week High/Low21.23 / 11.55 Price to Cash FLow (P/CF)
Data provided by IEX Cloud
View SEC Filings from IM3:FWB2 instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 62 -100.0% 0 (0.0%) 48 (2.99%) -100.0%
Funds Holding: 2 405 -99.51% (0.0%) 147 (9.15%)
13F shares: 371.681 Thousand 194.034 Million -99.81% 0 107.361 Million -100.0%
% Ownership 83.9403 46.4449
New Positions: 158 70
Increased Positions 86 32
Closed Positions 394 64 515.63% 145 30 383.33%
Reduced Positions 133 39
Total Calls 0 5.04 Million -100.0% 0 1.436 Million -100.0%
Total Puts 0 3.642 Million -100.0% 0 2.365 Million -100.0%
PUT/CALL Ratio 0.72 1.65
Heat Map Ranking 42
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding IM3:FWB2 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IM3:FWB2 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ISLAM KHALID

  • Director
0 2020-10-23 2

AGHAZADEH BEHZAD

AVORO CAPITAL ADVISORS LLC

  • Director
  • 10% Owner
  • SEE REMARKSSEE REMARKS
0 2020-10-23 2

CANUTE SCOTT A

  • Director
0 2020-10-23 2

HUTT PETER BARTON

  • Director
0 2020-10-23 2

DELANEY BRENDAN CHIEF COMMERCIAL OFFICER

  • Officer
0 2020-10-23 2

MALIK USAMA CHIEF FIN. & BUSINESS OFFICER

  • Officer
0 2020-10-23 2

FRICKER WILLIAM PRINCIPAL ACCOUNTING OFFICER

  • Officer
0 2020-10-23 1

FREEDBERG JARED GEN. COUNSEL & CORP. SECRETARY

  • Officer
0 2020-10-23 2

ANDREWS KURT J. CHIEF HUMAN RESOURCES OFFICER

  • Officer
0 2020-10-23 2

BAUM CHARLES M

  • Director
0 2020-10-23 2

DUNCAN BARBARA GAYLE

  • Director
0 2020-10-23 5

BALL BRYAN CHIEF QUALITY OFFICER

  • Officer
0 2020-10-23 2

ITRI LORETTTA M CHIEF MEDICAL OFFICER

  • Officer
0 2020-10-23 1

AZELBY ROBERT

  • Director
0 2020-10-23 2

SEMERJIAN HAROUT PRESIDENT AND CEO

  • Officer
  • Director
0 2020-04-16 2

ROSENBERG MORRIS CHIEF TECHNOLOGY OFFICER

  • Officer
0 2019-09-06 0

IANNONE ROBERT CHIEF MEDICAL OFFICER

  • Officer
0 2019-03-14 0

PEHL MICHAEL F. PRESIDENT AND CEO

  • Officer
0 2018-09-14 0

GOLDENBERG DAVID M

  • Director
7,387,537 2018-02-28 0

MARKISON BRIAN A

  • Director
90,788 2017-11-20 0

AGHAZADEH BEHZAD

  • Director
  • 10% Owner
  • SEE REMARKS
16,064,461 2017-11-14 2

VENBIO SELECT ADVISOR LLC

  • Director
  • 10% Owner
  • SEE REMARKS
16,064,461 2017-11-14 2

GOLDENBERG CYNTHIA L

  • Director
5,906,233 2017-08-31 0

GARONE MICHAEL CHIEF FINANCIAL OFFICER

  • Officer
0 2017-07-03 0

STARK DON C

  • Director
No longer subject to file 2017-06-30 0

COX GEOFFREY F

  • Director
0 2017-01-08 0

FORRESTER ROBERT

  • Director
0 2017-01-08 0

ARYEH JASON

  • Director
0 2017-01-08 0

OLIVER BOB

  • Director
0 2017-01-08 0

PAETZOLD MARY E

  • Director
78,325 2016-12-02 0

KIRSCH ARTHUR S

  • Director
0 2015-12-02 0

SHERMAN RICHARD L.

  • Director
No longer subject to file 2015-12-01 0

PFREUNDSCHUH PETER P. CHIEF FINANCIAL OFFICER

  • Officer
29,706 2015-08-20 0

COLEMAN MORTON

  • Director
No longer subject to file 2013-12-04 0

LOCASTRO MARCELLA

  • Director
No longer subject to file 2013-12-04 0

GORMAN GERARD G SVP, FIN. , AND CFO

  • Officer
0 2013-08-16 0

ZUERBLIS KENNETH J

  • Director
9,167 2011-12-07 0

WOLYNIC EDWARD T

  • Director
6,667 2009-12-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
American Century Quantitative Equity Funds, Inc.- AC Alternatives Equity Market Neutral Fund IM3:FWB2 -4999.0 shares, $-105778.84 2019-12-31 N-PORT
American Century Quantitative Equity Funds, Inc.- AC Alternatives Disciplined Long Short Fund IM3:FWB2 -4122.0 shares, $-87221.52 2019-12-31 N-PORT
American Century Quantitative Equity Funds, Inc.- Core Equity Plus Fund IM3:FWB2 -27324.0 shares, $-362316.24 2019-09-30 N-PORT
AGF Investments Trust- AGFIQ U.S. Market Neutral Value Fund IM3:FWB2 -73.0 shares, $-6207.19 2020-09-30 N-PORT
American Century Quantitative Equity Funds, Inc.- NT Core Equity Plus Fund IM3:FWB2 -83315.0 shares, $-1104756.9 2019-09-30 N-PORT
Trust for Professional Managers- Convergence Market Neutral Fund IM3:FWB2 -1592.0 shares, $-70939.52 2020-08-31 N-PORT
AQR Funds- AQR Small Cap Relaxed Constraint Equity Fund IM3:FWB2 -50.0 shares, $-663.0 2019-09-30 N-PORT

Elevate your investments